Skip to content

Telecoaching Plus a Portion Control Device for Weight Management in the Primary Care Setting

Telecoaching Plus a Portion Control Device for Weight Care Management

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02373878
Enrollment
90
Registered
2015-02-27
Start date
2011-05-31
Completion date
2012-06-30
Last updated
2015-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

The purpose of this study was to evaluate the impact of telecoaching conducted by a counselor trained in motivational interviewing paired with a portion control device for obese patients receiving care in a certified patient-centered medical home. The investigators will conduct a randomized, controlled clinical trial evaluating the effectiveness of a telecoaching intervention with a portion control device.

Detailed description

The intervention will be provided during a 3-month period with follow-up through 6 months after randomization. Body mass index (BMI) and waist circumference measurements will be collected at baseline and at 6, 12, 18, and 24 weeks. Participants will also complete measures assessing eating behaviors and physical activity at baseline and at 12 and 24 weeks.

Interventions

BEHAVIORALTelecoaching plus Plate

A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.

BEHAVIORALUsual Care

Subjects were provided with institutional pamphlets on healthy eating and exercise habits

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Men or women ≥ 18 years and ≤ 55 years of age * A BMI of ≥ 30 and ≤ 44.9 kg/m2 * Motivated to lose weight * Able to participate fully in all aspects of the study; * Have been provided with, understand, and have signed the informed consent.

Exclusion criteria

* Unstable angina, myocardial infarction, or coronary angioplasty within the past 3 months or an untreated cardiac dysrhythmia * A history of a gastric bypass procedure or planned gastric bypass * Baseline systolic blood pressure \> 180 or diastolic \> 100 * Another member of their household already participating in this study * Current treatment with another investigational drug for obesity (within 30 days of study entry) * Are pregnant or lactating * History of anorexia or bulimia * Current binge eating disorder as assessed by the Patient Health Questionnaire eating disorder module (PHQ-ED) * Schizophrenia or bipolar disorder or have a PHQ-2 ≥ 337 * Have been diagnosed with cancer within the past 5 years * Are currently participating in a program specifically to lose weight or are on a weight loss medication (last 30 days)

Design outcomes

Primary

MeasureTime frame
Change in Body Mass IndexBaseline, 3 months and 6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026